Lipid-lowering drug therapy: Which drug to choose

Dr Lale Tokgozoglu is a professor of medicine in the Department of Cardiology at Hacettepe University (Turkey), president of the European Atherosclerosis Society (EAS), and author of guidelines on dyslipidemia from the EAS and the European Society of Cardiology (ESC).

See also

Pharmacotherapy in young patients with hypertension and no other risk factors When should we start pharmacotherapy in young patients with hypertension and no other cardiovascular risk factors?
Current management of syncope: Key practical messages from the latest guidelines A lecture by Dr Giorgio Costantino, from the University of Milan, Italy, delivered at McMaster International Review Course in Internal Medicine (MIRCIM) in May 2019.
New definition of myocardial infarction and its practical implications A lecture by Dr P.J. Devereaux, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine (MIRCIM) in May 2019.
Duration of dual antiplatelet therapy after PCI What should be the duration of dual antiplatelet therapy in patients after percutaneous coronary interventions (PCIs)?
Hypertension: treatment for compelling indications A lecture by Dr Ally Prebtani, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2018.
Secondary prevention of cardiovascular diseases: current state-of-art A lecture by Dr Gerd Hasenfuß, from the University of Göttingen, Germany, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2018.
How to keep patients with chronic heart failure out of hospital A lecture by Dr Harriette Van Spall, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2018.

Lipid-lowering drug therapy: Which drug to choose

Social Media